Patents by Inventor Mary A. Cotter

Mary A. Cotter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120041010
    Abstract: The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes
    Type: Application
    Filed: March 15, 2011
    Publication date: February 16, 2012
    Inventors: Norman E. Cameron, Mary A. Cotter
  • Patent number: 8003090
    Abstract: The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: August 23, 2011
    Assignee: Merck Serono SA
    Inventors: Michel Dreano, Pierre-Alain Vitte, Norman Cameron, Mary A. Cotter
  • Publication number: 20090186908
    Abstract: The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.
    Type: Application
    Filed: August 11, 2008
    Publication date: July 23, 2009
    Inventors: Norman E. Cameron, Mary A. Cotter
  • Publication number: 20080107621
    Abstract: The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.
    Type: Application
    Filed: August 30, 2005
    Publication date: May 8, 2008
    Applicants: APPLIED RESEARCH SYSTEMS ARS HOLDING S.A., LABORATOIRES SERONO SA
    Inventors: Michel Dreano, Pierre-Alain Vitte, Norman Cameron, Mary A. Cotter
  • Publication number: 20050209128
    Abstract: The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.
    Type: Application
    Filed: September 8, 2004
    Publication date: September 22, 2005
    Inventors: Norman Cameron, Mary Cotter
  • Patent number: 6894058
    Abstract: The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: May 17, 2005
    Assignee: AstraZeneca AB
    Inventors: Norman E. Cameron, Mary A. Cotter
  • Patent number: 6069168
    Abstract: Use of 6-desaturated n-6 fatty acids, especially gammalinolenic acid (GLA), dihomogammalinolenic acid (DGLA) or arachidonic acid (AA), together with a pharmaceutically acceptable material reducing intracellular levels of sorbitol in the body, particularly an aldose reductase inhibitor, in the treatment of (including prophylactic treatment), and in the preparation of medicaments for the treatment of (including prophylactic treatment), the long-term complications of diabetes mellitus. Pharmaceutical compositions of said materials. The ascorbate esters of 6-desaturated n-6 fatty acids (other than GLA or DGLA) per se.
    Type: Grant
    Filed: February 6, 1997
    Date of Patent: May 30, 2000
    Assignee: Scotia Holdings Plc
    Inventors: David Frederick Horrobin, Mary Cotter, Norman Cameron